Altitudinal Glaucoma - Symptoms, Causes, Treatment & Prevention

Overview

Altitudinal glaucoma is a rare subset of primary open‑angle glaucoma (POAG) in which the visual field loss occurs preferentially in the upper or lower half of the retina, producing a characteristic “altitudinal” defect. Unlike typical glaucomatous damage that often starts in the peripheral vision and progresses in a curvilinear pattern, altitudinal glaucoma leads to a sharp horizontal line of loss, similar to the pattern seen after a retinal vascular occlusion.

It most commonly affects adults over the age of 50, but cases have been reported in younger patients with congenital or secondary forms of glaucoma. The exact prevalence is difficult to determine because it is usually classified under broader glaucoma categories in epidemiologic studies. In large population‑based surveys, POAG accounts for 2–3 % of the adult population worldwide; altitudinal patterns are observed in roughly 5–10 % of those POAG cases, translating to an estimated prevalence of 0.1–0.3 % of adults ^[1][2].

Because the disease attacks the optic nerve fibers that serve one half of the retina, patients may experience a sudden or progressive loss of vision in either the upper or lower visual field, often without eye pain or redness. Early detection is essential—once optic nerve fibers die, the loss is permanent.

Symptoms

Symptoms of altitudinal glaucoma are similar to other glaucomas but have a distinctive visual‑field pattern. Patients may notice:

• Half‑field vision loss – a horizontal “cut‑off” in either the upper or lower visual field. For example, the patient may be unable to see objects that are above the waistline (superior altitudinal defect) or below it (inferior altitudinal defect).
• Difficulty with stairs – trouble seeing steps when going up or down, especially if the defect is inferior.
• Problems with reading – missing words or lines if the defect involves the lower visual field.
• Distorted perception of objects – straight lines may appear bent near the edge of the affected field.
• Night‑time visual difficulties – especially with inferior defects, because peripheral vision helps with low‑light navigation.
• Eye discomfort (rare) – occasional mild pressure sensation; pain is not typical unless intra‑ocular pressure (IOP) spikes dramatically.
• No pain, redness, or discharge – unlike acute angle‑closure glaucoma, altitudinal glaucoma is painless.

These symptoms often develop slowly, and many patients attribute them to normal aging. Routine visual‑field testing is the only reliable way to recognize an altitudinal pattern before it progresses.

Causes and Risk Factors

Altitudinal glaucoma is fundamentally a form of optic‑nerve damage caused by elevated intra‑ocular pressure (IOP) or vascular insufficiency. The following mechanisms are most commonly implicated:

Primary causes

1. Elevated IOP (primary open‑angle glaucoma) – chronic pressure elevation leads to mechanical stress on the lamina cribrosa, preferentially affecting the superior or inferior nerve fiber bundles.
2. Vascular dysregulation – impaired blood flow to the optic nerve head can produce focal ischemia that mimics an altitudinal defect, especially in patients with systemic hypertension, diabetes, or sleep‑apnea.
3. Structural optic‑nerve anomalies – congenital optic disc cupping or myopic optic disc tilt can predispose certain nerve fiber layers to damage.

Risk factors

• Age ≥ 50 years (risk rises ~1.5‑fold per decade after age 40) ^[3]
• Family history of glaucoma (first‑degree relative)
• African, Hispanic, or Asian ancestry (higher POAG rates)
• Myopia (especially > -3.00 D)
• Elevated IOP > 21 mmHg on at least two separate visits
• Systemic hypertension, diabetes mellitus, or hyperlipidemia (vascular component)
• Use of corticosteroids (topical, oral, or inhaled) for > 3 months
• History of ocular trauma or intra‑ocular surgery

Diagnosis

Diagnosing altitudinal glaucoma involves a combination of history, clinical examination, and specialized testing to document the characteristic half‑field loss.

Step‑by‑step diagnostic approach

1. Comprehensive eye exam – visual acuity, slit‑lamp evaluation of the anterior segment, and gonioscopy to confirm an open angle.
2. Intra‑ocular pressure measurement – Goldmann applanation tonometry is the gold standard; repeat measurements on different days help confirm chronic elevation.
3. Optic‑nerve head assessment – dilated fundus examination and stereoscopic optic‑disc photography to evaluate cupping, rim thinning, and retinal nerve‑fiber layer (RNFL) defects.
4. Automated visual‑field testing – Humphrey Field Analyzer (24‑2 or 30‑2) or Octopus perimeter. The hallmark is a horizontal line of loss with at least one hemifield showing a mean deviation (MD) ≥ -6 dB while the opposite field remains relatively normal.
5. Optical coherence tomography (OCT) – high‑resolution imaging of the RNFL and ganglion‑cell complex. Altitudinal loss is seen as sectoral thinning corresponding to the affected hemifield.
6. Anterior‑segment OCT or ultrasound biomicroscopy – if angle‑closure or plateau‑iris suspect; usually normal in altitudinal POAG.
7. Systemic work‑up (if vascular cause suspected) – blood pressure monitoring, fasting glucose, lipid profile, and possibly a sleep study for obstructive sleep apnea.

All findings are recorded in the patient's chart and compared over time to detect progression. The disease is considered “progressive” if there is a statistically significant decline in visual‑field indices or RNFL thickness on serial testing.

Treatment Options

Management aims to lower IOP to a level that halts further optic‑nerve damage while preserving the existing visual field.

Medications

• Prostaglandin analogues (latanoprost, tafluprost, bimatoprost) – first‑line; reduce IOP by increasing uveoscleral outflow. Typical target reduction: 25‑30 %.
• Beta‑blockers (timolol, betaxolol) – decrease aqueous production; useful as adjuncts.
• Alpha‑agonists (brimonidine) – both decrease production and increase outflow; may cause dry mouth.
• Carbonic anhydrase inhibitors (brinzolamide, dorzolamide) – topical agents; oral acetazolamide reserved for acute pressure spikes.
• Rho‑kinase inhibitors (netarsudil) – newer class that improves trabecular outflow.

Combination drops (e.g., prostaglandin‑beta‑blocker) improve adherence and provide greater pressure lowering.

Laser and Surgical Procedures

1. Selective laser trabeculoplasty (SLT) – first‑line laser for patients who need additional IOP reduction or who cannot tolerate drops. Shrinks trabecular meshwork cells, enhancing outflow.
2. Micropulse laser cyclophotocoagulation – reserved for refractory cases; reduces aqueous production with less inflammation.
3. Trabeculectomy – filtration surgery creating a drainage bleb; success rates 70‑80 % for IOP < 15 mmHg in advanced disease.
4. Glaucoma drainage devices (tube shunts) – Ahmed, Baerveldt, or Molteno implants; indicated when conjunctival scarring limits trabeculectomy.
5. – iStent, Hydrus, or Xen gel stent; smaller incision, quicker recovery, suitable for mild‑to‑moderate disease.

Lifestyle and Adjunctive Measures

• Adopt a low‑salt, Mediterranean‑style diet rich in antioxidants (leafy greens, berries, omega‑3 fatty acids) to support vascular health.
• Engage in moderate aerobic exercise (150 min/week) – improves ocular blood flow and may modestly lower IOP.
• Limit caffeine to < 200 mg per day; excess caffeine can raise IOP transiently.
• Avoid systemic steroids when possible; discuss alternatives with your physician.
• Protect eyes from trauma (safety glasses) and wear UV‑blocking sunglasses.

Living with Altitudinal Glaucoma

Even after diagnosis and treatment, many patients can maintain independence and a high quality of life with appropriate strategies:

• Regular monitoring – schedule visual‑field and OCT tests every 6–12 months, or more frequently if progression is noted.
• Adherence to medication – use a pill/eye‑drop organizer, set smartphone reminders, and keep a medication log.
• Home modifications – improve lighting, add contrasting strips on stairs, and use tactile floor markers for patients with inferior field loss.
• Driving assessment – obtain a professional evaluation; some jurisdictions require a visual‑field test for licensing.
• Vision‑rehabilitation services – low‑vision therapists can teach scanning techniques, use of prisms, and adaptive technology (screen readers, magnifiers).
• Support groups – connect with organizations such as Glaucoma Foundation or local eye‑health NGOs for emotional support and updates on research.

Prevention

While you cannot change age or genetics, several actions can reduce the risk of developing altitudinal (or any) glaucoma:

1. Annual comprehensive eye exams after age 40; earlier if you have risk factors.
2. Screen for elevated IOP if you have a family history.
3. Control systemic diseases – keep blood pressure, blood sugar, and cholesterol within target ranges.
4. Maintain a healthy weight – obesity is linked to higher IOP.
5. Avoid smoking – smoking worsens vascular supply to the optic nerve.
6. Use steroids judiciously – discuss eye‑drop alternatives with your ophthalmologist.

Complications

If left untreated or inadequately controlled, altitudinal glaucoma can lead to:

• Progressive visual‑field loss that may extend to the opposite hemifield, resulting in severe binocular blindness.
• Legal blindness (visual acuity < 20/200) or inability to perform activities of daily living.
• Falls and injuries – especially with inferior field loss, increasing risk of tripping on obstacles.
• Reduced quality of life – loss of independence, depression, and anxiety are common in advanced glaucoma.
• Secondary ocular complications from surgeries (e.g., bleb leaks, infection, hypotony).

When to Seek Emergency Care

References

1. American Academy of Ophthalmology. Primary Open‑Angle Glaucoma Preferred Practice Pattern. 2023.
2. World Health Organization. Worldwide Prevalence of Glaucoma. WHO Glaucoma Fact Sheet, 2022.
3. Mayo Clinic. Glaucoma – Statistics and Risk Factors. Updated 2024.
4. Cleveland Clinic. Visual‑Field Testing for Glaucoma. 2024.
5. National Eye Institute (NIH). Glaucoma Overview. 2023.